Overcoming Solubility Challenges: Liposomal isoCoQ‐Carbazole as a Promising Anti‐Tumor Agent for Inoperable and Radiation‐Insensitive cancers

Abstract

AbstractThis study evaluated the potential of isoCoQ‐Carbazole, a diheterocyclic analog of isoCA‐4, as an anti‐tumor agent. To overcome its low aqueous solubility, liposomes were developed as a delivery system for the compound. In vitro experiments showed that loaded liposomes exhibited similar activity to the free form on multiple human tumor cell lines. In vivo experiments using a palliative intratumoral injection chemotherapy approach further demonstrated that isoCoQ‐Carbazole loaded liposomes significantly reduced tumor growth in a CA‐4‐resistant HT29 cell model, without inducing any observable toxicity or weight loss in the treated mice. These findings suggest that liposomal isoCoQ‐Carbazole may hold promise as a potential therapeutic agent for the treatment of inoperable, radiation‐insensitive cancers.